Use of Letermovir as Salvage Therapy for Drug-Resistant Cytomegalovirus Retinitis.
Published online
Journal Article
Treatment options for drug-resistant cytomegalovirus (CMV) are limited. Letermovir is a novel antiviral recently approved for CMV prophylaxis following hematopoietic cell transplantation, but its efficacy in other settings is unknown. We recently used letermovir for salvage treatment in four solid organ transplant recipients with ganciclovir-resistant CMV retinitis. All patients improved clinically without known adverse drug events. However, three patients failed to maintain virologic suppression, including two patients who developed genotypically confirmed resistance to letermovir while on therapy.
Full Text
- Published version (via Digital Object Identifier)
- Pubmed Central version
- Open Access Copy from Duke
- Link to Item
Duke Authors
- Arif, Sana
- Baker, Arthur Wakefield
- Grewal, Dilraj Singh
- Maziarz, Eileen
- Saullo, Jennifer H.
- Turner, Nicholas
- Wolfe, Cameron Robert
Cited Authors
- Turner, N; Strand, A; Grewal, DS; Cox, G; Arif, S; Baker, AW; Maziarz, EK; Saullo, JH; Wolfe, CR
Published Date
- March 2019
Published In
Volume / Issue
- 63 / 3
PubMed ID
- 30642941
Pubmed Central ID
- 30642941
Electronic International Standard Serial Number (EISSN)
- 1098-6596
Digital Object Identifier (DOI)
- 10.1128/AAC.02337-18
Language
- eng
Conference Location
- United States